Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neuroblastoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Combined Modality Therapy × 1 year × Clear all
NCT07610616 2026-05-28

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

Guangzhou Institute of Respiratory Disease

Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07393477 2026-02-06

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

Sir Run Run Shaw Hospital

Phase 2 Not yet recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡